December 11th, 2014
Johnson & Johnson and USAID Partner to Address the Global Health Threat of Antibiotic-Resistant Bacteria
Among my lifelong goals is to advance progress in new treatment options for patients living with the world’s most serious health threats. Antimicrobial resistance is responsible for many of them, especially in communities with limited resources and fragmented healthcare infrastructures. When resistance limits first- and second-line options, healthcare providers must opt for less desirable alternatives,1 which often lead to worsened patient outcomes.
Over many years of researching and learning, the complexities of infectious diseases have become clear to me. Despite the development of new treatments to address ever-expanding forms of antimicrobial resistance, the ability to scale up appropriate use of treatment regimens remains challenging.
According to the 2013 Antibiotic Resistance Threats in the United States report, approximately 250,000 antimicrobial infections each year require hospitalization, or are already affecting hospitalized patients, who also already have weakened immune systems.1 These infections should command our complete attention especially because the threat can reach us all – almost half of infections occur in people younger than 65, and more than 90 percent of deaths occur in people 65 and older.1
Given the hardships of combating antimicrobial resistance, we are proud to announce our pharmaceutical company, Janssen, has signed a memorandum of understanding (MOU) for a collaboration with the United States Agency for International Development (USAID) to help address the global health threat of antibiotic-resistant bacteria.